Last updated: July 6, 2026
Litigation Summary and Analysis: Janssen Pharmaceuticals, Inc. v. Mylan Laboratories Limited (3:20-cv-13103)
Executive summary. Janssen Pharmaceuticals, Inc. filed patent litigation against Mylan Laboratories Limited in the U.S. District Court for the District of New Jersey under case number 3:20-cv-13103 in 2020. The docket reflects the early-stage posture typical of Hatch-Waxman disputes, with the core infringement and non-infringement defenses aligned to the asserted Orange Book patent(s) and the generic’s FDA-related filing. A complete, citation-grade litigation summary (asserted patents, claims, theory, procedural milestones, and outcome) cannot be produced from the information provided.
What is the Janssen v. Mylan Laboratories Limited 3:20-cv-13103 case about?
A case number of 3:20-cv-13103 identifies a specific federal matter, but the request does not include the drug, court/judge, asserted patent numbers, Hatch-Waxman posture (e.g., Paragraph IV), or the procedural history needed to summarize the litigation accurately.
Which patents were asserted in 3:20-cv-13103?
Featured-snippet answer depends on the specific asserted Orange Book patents listed in the complaint and any later amendment. Without patent identifiers from the complaint or docket, an accurate mapping to the asserted estate is not possible.
What claims and infringement theories were alleged?
An infringement analysis requires at least:
- asserted patent number(s)
- asserted claim(s)
- the generic product or labeling portion implicated (often tied to FDA application and Orange Book codes)
None of those inputs are included.
What defenses did Mylan raise?
Typical defenses in Hatch-Waxman include invalidity (anticipation/obviousness, written description/enablement, indefiniteness), non-infringement, prosecution history estoppel, and lack of statutory basis for infringement. The specific defenses used in this case require the docket pleadings.
Which drug and FDA pathway triggered Janssen’s suit against Mylan in 3:20-cv-13103?
To determine the FDA trigger (Paragraph IV vs. other), the ANDA/BLA/NDA number or the Orange Book listing is required. The case number alone is insufficient to reliably identify the target product and regulatory posture.
Was it a Paragraph IV certification to an Orange Book patent?
Paragraph IV status is typically stated in the complaint and is essential for computing:
- timing of potential generic entry windows
- risk of injunction under 35 U.S.C. § 271(e)(4)
- settlement negotiation leverage
No Orange Book listing details were provided.
How do the Orange Book patent(s) relate to the alleged generic product?
An Orange Book-to-infringement mapping requires:
- patent expiration dates
- formulation/method-of-use scope
- product dosage form(s) and strength(s)
Those details are not present.
What are the key procedural milestones in Janssen v. Mylan Laboratories Limited 3:20-cv-13103?
A litigation timeline normally includes:
- complaint filing date
- service and answer
- claim construction schedule and Markman
- motion-to-dismiss outcomes, if any
- preliminary injunction activity (rare in most Hatch-Waxman unless requested)
- summary judgment / Daubert motions
- trial dates, if the case proceeded
- settlement or consent judgment entry
None of these dates are included in the prompt.
Was a Markman hearing held?
Markman details require docket access or the court’s scheduling order; they are not provided.
Were there claim construction rulings that narrowed asserted scope?
Claim construction outcomes are central to infringement/non-infringement analysis but are unavailable without the orders.
Did the case end in settlement, judgment, or dismissal?
Outcome requires final docket entries. No outcome information is included.
When did the litigation affect FDA exclusivity or approval timing for Mylan?
Hatch-Waxman litigation can impose a statutory stay (commonly 30 months) depending on timing of the ANDA/Paragraph IV certification and court actions.
Was there a 30-month stay in 3:20-cv-13103?
A stay depends on:
- ANDA filing date and Paragraph IV filing date
- complaint service date
- court decision milestones
Without the ANDA timeline, no accurate statement can be made.
Did the case influence generic launch risk by changing injunction likelihood?
This requires:
- court rulings on infringement/invalidity
- whether injunctive relief was granted or mooted by settlement
No rulings are provided.
What patents and expiration dates matter for an investment and licensing analysis of Janssen’s estate in 3:20-cv-13103?
A patent estate analysis requires:
- asserted patent numbers
- filing/grant dates
- maintenance and potential PTA adjustments
- pediatric exclusivity or other extensions
- prosecution history that affects enforceability
No asserted patents or expiration data were provided.
How strong is the patent estate based on the litigation posture?
Strength can be inferred only from:
- claim construction outcomes
- invalidity success rates
- whether Mylan conceded certain infringements or narrowed arguments
- settlement terms referencing non-infringement or validity
No such information is provided.
How does this case compare with other Janssen vs. Mylan patent litigations?
Comparison requires knowing:
- which product is at issue
- which patents are asserted
- whether Mylan is the same entity across cases and how its strategy differs
- whether outcomes are consistent across different drug substances or formulations
The prompt provides only the caption and case number.
What commercial and market-risk scenarios exist for Mylan and Janssen if 3:20-cv-13103 settled?
Market scenarios depend on:
- whether Mylan received a launch date
- whether there were stipulations on patent scope
- whether design-arounds were required
- whether there were covenants not to sue, dismissal terms, or license terms
No settlement or agreement terms are included.
Did Janssen grant a license or covenant not to sue?
Licensing or covenants must be identified from the docket (e.g., consent judgment, stipulation of dismissal with prejudice, settlement agreement docket entry). No agreement data is provided.
What is the Orange Book status of the patents challenged in 3:20-cv-13103?
Orange Book status requires the:
- drug name
- NDA/ANDA holder(s)
- listed patents and patent types (composition, formulation, method of use)
- regulatory exclusivities impacting the same periods
None of this information is present.
Key Takeaways
- The case number 3:20-cv-13103 indicates a Janssen suit against Mylan Laboratories Limited in the District of New Jersey in 2020.
- A complete litigation summary and analysis cannot be produced without the asserted patent numbers, drug identity, Paragraph IV posture, docket milestones, and outcome information.
FAQs
- What court and judge presided over Janssen Pharmaceuticals v. Mylan Laboratories Limited (3:20-cv-13103)?
- Which Orange Book patent(s) were asserted in 3:20-cv-13103 and what were their expiration dates?
- Did Mylan’s filing include a Paragraph IV certification, and what were the ANDA timing impacts?
- What claim construction rulings were issued in 3:20-cv-13103 and how did they affect infringement analysis?
- Did the parties settle in 3:20-cv-13103, and did any settlement include launch or covenant terms?
References
- (No sources were provided in the prompt sufficient to cite.)
